Aptorum Group Limited Class A Stock News

  Aptorum Group kooperiert mit Covar Pharmaceuticals bei der Erforschung von mindestens drei umgewidmeten Wirkstoffkandidaten (SACT-COV19) zur Behandl

  Aptorum Group colabora con Covar Pharmaceuticals en la investigación de al menos 3 candidatos a fármacos reutilizados (SACT-COV19) para la enfermeda

  Le Groupe Aptorum collabore avec Covar Pharmaceuticals pour étudier au moins 3 candidats-médicaments reconvertis (SACT-COV19) pour le traitement du

NEW YORK — Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not li…

Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and

Aptorum Group Ltd (NASDAQ:APM) saw a significant decline in short interest during the month of March. As of March 13th, there was short interest totalling 18,600 shares, a decline of 31.6% from the Fe

Instana, the leading provider of real-time application performance management (APM) solutions for cloud-native microservice applications, today announced an extension of the company's one-click integr

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on Mar

Aptorum Group Ltd (NASDAQ:APM) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 27,200 shares, a decline of 9.3% from the

Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of Aptorum Group Limited...

ValuEngine upgraded shares of Aptorum Group (NASDAQ:APM) from a hold rating to a buy rating in a research report sent to investors on Wednesday, ValuEngine reports. Shares of APM opened at $6.00 on We

Aptorum Group Limited (NASDAQ:APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the closing of

Aptorum Group Ltd (NASDAQ:APM) saw a large growth in short interest in the month of February. As of February 14th, there was short interest totalling 21,100 shares, a growth of 40.7% from the January

Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the pricing o

Společnost Aptorum Group Limited (dále jen